Wall Street analysts expect Accelerate Diagnostics Inc (NASDAQ:AXDX) to post earnings per share (EPS) of ($0.39) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Accelerate Diagnostics’ earnings. The lowest EPS estimate is ($0.44) and the highest is ($0.29). Accelerate Diagnostics reported earnings of ($0.41) per share in the same quarter last year, which would indicate a positive year over year growth rate of 4.9%. The firm is expected to report its next earnings report on Tuesday, November 5th.
On average, analysts expect that Accelerate Diagnostics will report full-year earnings of ($1.58) per share for the current year, with EPS estimates ranging from ($1.65) to ($1.45). For the next financial year, analysts anticipate that the business will report earnings of ($1.57) per share, with EPS estimates ranging from ($1.67) to ($1.49). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Accelerate Diagnostics.
Accelerate Diagnostics (NASDAQ:AXDX) last released its earnings results on Thursday, August 8th. The medical research company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.02. Accelerate Diagnostics had a negative return on equity of 170.47% and a negative net margin of 1,293.91%. The firm had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $2.71 million.
A number of institutional investors and hedge funds have recently bought and sold shares of AXDX. Chicago Capital LLC grew its holdings in Accelerate Diagnostics by 10.6% in the 2nd quarter. Chicago Capital LLC now owns 546,279 shares of the medical research company’s stock valued at $12,499,000 after buying an additional 52,460 shares in the last quarter. M&T Bank Corp bought a new stake in shares of Accelerate Diagnostics during the 2nd quarter worth $206,000. First Trust Advisors LP bought a new stake in shares of Accelerate Diagnostics during the 2nd quarter worth $2,570,000. C WorldWide Group Holding A S lifted its position in shares of Accelerate Diagnostics by 357.5% during the 2nd quarter. C WorldWide Group Holding A S now owns 524,683 shares of the medical research company’s stock worth $12,005,000 after buying an additional 410,000 shares during the last quarter. Finally, Griffin Asset Management Inc. lifted its position in shares of Accelerate Diagnostics by 11.1% during the 1st quarter. Griffin Asset Management Inc. now owns 484,871 shares of the medical research company’s stock worth $10,192,000 after buying an additional 48,352 shares during the last quarter. Institutional investors and hedge funds own 54.02% of the company’s stock.
Shares of Accelerate Diagnostics stock traded up $0.02 on Wednesday, reaching $21.34. 164,298 shares of the company were exchanged, compared to its average volume of 253,196. Accelerate Diagnostics has a one year low of $10.23 and a one year high of $24.00. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -13.17 and a beta of 2.71. The company has a current ratio of 19.99, a quick ratio of 18.89 and a debt-to-equity ratio of 4.81. The company has a 50-day moving average of $18.48 and a 200 day moving average of $19.56.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Featured Story: What is a Tariff?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.